Clinical Trial Update: An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease [Phase 3]

View source ↗

Summary

An extension phase 3 trial update to evaluate the long-term safety of Fazirsiran and its potential ongoing benefit for people with Alpha-1 antitrypsin deficienc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alpha-1 Antitrypsin Deficiency
• Alpha-1 Antitrypsin Liver Disease

Drugs mentioned

• Fazirsiran (fazirsiran)

Snippet

Sponsor: Takeda | Conditions: Alpha1-Antitrypsin Deficiency | Phase 3 | Status: ACTIVE_NOT_RECRUITING